Mizuho Downgrades Revance Therapeutics to Neutral, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Vamil Divan has downgraded Revance Therapeutics (NASDAQ:RVNC) from Buy to Neutral and reduced the price target from $16 to $9, indicating a more cautious outlook on the company's stock.
January 29, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Revance Therapeutics was downgraded by Mizuho from Buy to Neutral, with a price target reduction from $16 to $9, suggesting a tempered expectation for the stock's performance.
Analyst downgrades typically lead to a negative short-term reaction in the stock market as they suggest a less optimistic view on the company's future performance. The reduction in price target further emphasizes the analyst's lowered expectations, which may influence investor sentiment and stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100